Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Avastin
 More »

  • Amgen Forms Joint Venture to Sell Vectibix in China
    faced stiff competition from other mCRC drugs, namely Avastin (bevacizumab), marketed by Roche, and Erbitux. However, Avastin and Erbitux are not yet sold in China, though they ...
    5-10-2013
  • Oncobiologics Finds Partner to Launch Biosimilars in U.S., China
    ... Zhejiang Huahai will also commercialize Humira, Rituxan, Avastin, and Herceptin for EU, Japan, Canada, and Australia. Oncobiologics Finds Partner to Launch Biosimilars in U.S., ...
    5-8-2013
  • Biosimilars: 10 Drugs to Watch
    ... have been announced in recent months: Avastin (Bevacizumab) : Amgen is developing a ... to develop a biosimilar version of Avastin (Roche / Genentech) for cancer ...
    4-22-2013
  • Top 20 Best-Selling Drugs of 2012
    ... 20.0% Q4 2012 sales: $1.420 billion, up 20.3% from $1.181 billion in Q4 2011 #9. Avastin (bevacizumab) Drug maker: Roche Indication(s): Metastatic colorectal cancer (colon ...
    3-1-2013
  • Top 10 Clinical Trial Failures of 2012
    in combination with Roche/Genentech's Avastin (bevacizumab); Second-line renal cell ... 12 for a third Phase III trial. #7. Avastin (bevacizumab) Sponsor: Roche (Genentech) ...
    2-1-2013
  • A "Very Good Year" for Roche
    Cancer drug Avastin was the company's third-best-selling drug at CHF 5.7 billion ($6.3 billion), up 6% from 2011, while sales of hepatitis C drug Pegasys grew 12% to CHF 1.6 ...
    1-30-2013
  • 15 Breast Cancer Drugs in the Pipeline Right Now
    cannot be removed completely by surgery Avastin (Bevacizumab; RG435) Sponsor: Roche/... Effectiveness based on tumor response, as no data have shown whether Avastin improves ...
    11-26-2012
  • EU Clears Avastin as Combo Therapy for Recurrent Ovarian Cancer
    The European Commission approved Roche's Avastin (bevacizumab) in combination with ... ovarian cancer who received the Avastin-chemotherapy combination demonstrated ...
    10-31-2012
  • Will FDA Bid Adieu to Auld Lang Syne and Open Up to New Drugs...
    ... the drug.Similarly mAb therapeutic Avastin lost its breast cancer approval last ... the same time that Avastin is losing its breast cancer approval (up to $100,000/year). ...
    9-5-2012
  • Some Better News for Avastin
    Roche and Genentech reported positive data from a Phase III trial of Avastin (bevacizumab) ... The newly reported Phase III AVAglio study assessed Avastin in addition to radiation and ...
    8-10-2012
  • Three Years After Merger, Genentech R&D Outshines That of Roche...
    One exception came last November, when FDA revoked its 2008 approval of Avastin (bevacizumab) with paclitaxel for the treatment of women with Her2-negative metastatic breast cancer ...
    7-3-2012
  • This Time Last Year: Diagnostic Deals, mAb Therapeutics, and...
    diagnostic alliance with Clovis, a melanoma deal with BMS, and FDA's Avastin decision. ... and Avastin losing FDA confidence with regard to its breast cancer indication. ...
    5-30-2012
  • Reports Acknowledge FDA Progress but Cite Concerns on Agency...
    ... such as the agency's revoking its approval in December of Avastin (bevacizumab) with chemo drug paclitaxel for treatment of women with Her2-negative metastatic breast cancer (MBC). ...
    5-21-2012
  • People in the News
    ... Boerner worked at Genentech for over eight years in various commerical roles, including director of marketing on Avastin. Simulations Plus elected David Ralph, Ph.D. , to its board ...
    4-15-2012
  • Roche Reports Sales Dip in First Quarter of This Year
    billion), also up 7%; and Avastin, up 1% at CHF 1.385 billion (almost $1.519 billion). ... at CHF 752 million ($824) and a flat result for Avastin at CHF 634 million ($695 million). ...
    4-12-2012
  • More »

    Journal Articles

  • Phacoemulcification with Intravitreal Bevacizumab Injection in...
    Ali Salehi, Afsaneh Naderi Beni, Hassan Razmjoo, Zahra Naderi Beni
    Journal of Ocular Pharmacology and Therapeutics
    (control group; 30 eyes) or to receive 1.25?mg intravitreal bevacizumab (0.05?mL of solution prepared from avastin, 100?mg/4?mL vial) at the end of surgery (IVB group; 27 eyes). ...
  • Simultaneous Intravitreal and Intracameral Injection of Bevacizumab...
    Erdal Yuzbasioglu, Ozgur Artunay, Rifat Rasier, Alper Sengul, Halil Bahcecioglu
    Journal of Ocular Pharmacology and Therapeutics
    Simultaneous Intravitreal and Intracameral Injection of Bevacizumab (Avastin) in ... injection of 1.25 mg bevacizumab (Avastin) in 15 neovascular glaucoma (NVG) cases ...
  • Effect of Intravitreal Bevacizumab (Avastin ® ) Therapy in Malignant...
    Eui Yon Kim, Ho Min Lew, Ji Hun Song
    Journal of Ocular Pharmacology and Therapeutics
    Effect of Intravitreal Bevacizumab (Avastin ® ) Therapy in Malignant Hypertensive Retinopathy: A Report of Two Cases Journal of Ocular Pharmacology and Therapeutics Abstract ...
  • Genetic Delivery of Bevacizumab to Suppress Vascular Endothelial...
    Masaki Watanabe, Julie L. Boyer, Ronald G. Crystal
    Human Gene Therapy and Part B: Methods
    treated intravenously with AdaVEGFAb, an adenoviral vector encoding the light and heavy chains of an anti-human VEGF antibody with the bevacizumab (Avastin) antigen-binding site. ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll